|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
61,660,000 |
Market
Cap: |
47.61(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6394 - $5.82 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
2,930,870 |
2,930,870 |
Total Buy Value |
$0 |
$0 |
$10,990,763 |
$10,990,763 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
49,511 |
191,640 |
263,030 |
1,586,782 |
Total Sell Value |
$37,495 |
$144,338 |
$351,679 |
$10,312,191 |
Total People Sold |
4 |
4 |
4 |
7 |
Total Sell Transactions |
20 |
38 |
59 |
108 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Miller Edward |
General Counsel |
|
2024-01-04 |
4 |
S |
$0.64 |
$271 |
D/D |
(424) |
235,534 |
|
-17% |
|
Brainard Diana |
Chief Executive Officer |
|
2024-01-04 |
4 |
S |
$0.64 |
$1,063 |
D/D |
(1,664) |
873,242 |
|
-17% |
|
Sinha Vikas |
See Remarks |
|
2024-01-04 |
4 |
S |
$0.64 |
$614 |
D/D |
(961) |
1,166,788 |
|
-17% |
|
Hagen Brett R |
Chief Accounting Officer |
|
2024-01-04 |
4 |
S |
$0.64 |
$198 |
D/D |
(310) |
97,190 |
|
-17% |
|
Hagen Brett R |
Chief Accounting Officer |
|
2023-12-27 |
4 |
S |
$0.74 |
$20,838 |
D/D |
(28,335) |
97,500 |
|
-12% |
|
Brainard Diana |
Chief Executive Officer |
|
2023-11-20 |
4 |
S |
$1.69 |
$7,408 |
D/D |
(4,382) |
874,906 |
|
53% |
|
Hagen Brett R |
Chief Accounting Officer |
|
2023-11-17 |
4 |
S |
$1.63 |
$657 |
D/D |
(403) |
125,835 |
|
51% |
|
Brainard Diana |
Chief Executive Officer |
|
2023-11-17 |
4 |
S |
$1.63 |
$4,386 |
D/D |
(2,689) |
879,288 |
|
51% |
|
Sinha Vikas |
See Remarks |
|
2023-11-17 |
4 |
S |
$1.63 |
$4,061 |
D/D |
(2,490) |
1,167,749 |
|
51% |
|
Hagen Brett R |
Chief Accounting Officer |
|
2023-10-20 |
4 |
S |
$1.54 |
$550 |
D/D |
(357) |
126,238 |
|
50% |
|
Sinha Vikas |
See Remarks |
|
2023-10-20 |
4 |
S |
$1.54 |
$2,273 |
D/D |
(1,475) |
1,170,239 |
|
50% |
|
Brainard Diana |
Chief Executive Officer |
|
2023-10-19 |
4 |
S |
$1.58 |
$13,558 |
D/D |
(8,581) |
881,977 |
|
53% |
|
Hagen Brett R |
Chief Accounting Officer |
|
2023-10-19 |
4 |
S |
$1.58 |
$566 |
D/D |
(358) |
126,595 |
|
53% |
|
Sinha Vikas |
See Remarks |
|
2023-10-19 |
4 |
S |
$1.58 |
$1,947 |
D/D |
(1,232) |
1,171,714 |
|
53% |
|
Sinha Vikas |
See Remarks |
|
2023-10-03 |
4 |
S |
$1.98 |
$1,492 |
D/D |
(755) |
1,172,946 |
|
66% |
|
Brainard Diana |
Chief Executive Officer |
|
2023-10-03 |
4 |
S |
$1.98 |
$2,619 |
D/D |
(1,325) |
890,558 |
|
66% |
|
Hagen Brett R |
Chief Accounting Officer |
|
2023-10-03 |
4 |
S |
$1.98 |
$439 |
D/D |
(222) |
126,953 |
|
66% |
|
Brainard Diana |
Chief Executive Officer |
|
2023-08-18 |
4 |
S |
$2.79 |
$11,313 |
D/D |
(4,055) |
891,883 |
|
75% |
|
Sinha Vikas |
See Remarks |
|
2023-08-17 |
4 |
S |
$2.50 |
$26,243 |
D/D |
(10,516) |
1,173,701 |
|
70% |
|
Brainard Diana |
Chief Executive Officer |
|
2023-08-17 |
4 |
S |
$2.50 |
$28,351 |
D/D |
(11,361) |
895,938 |
|
70% |
|
Hagen Brett R |
Chief Accounting Officer |
|
2023-08-17 |
4 |
S |
$2.50 |
$4,125 |
D/D |
(1,653) |
127,175 |
|
70% |
|
Sinha Vikas |
See Remarks |
|
2023-07-20 |
4 |
S |
$3.35 |
$4,810 |
D/D |
(1,437) |
1,184,217 |
|
53% |
|
Hagen Brett R |
Chief Accounting Officer |
|
2023-07-20 |
4 |
S |
$3.35 |
$1,145 |
D/D |
(342) |
128,828 |
|
53% |
|
Sinha Vikas |
See Remarks |
|
2023-07-19 |
4 |
S |
$3.56 |
$4,267 |
D/D |
(1,198) |
1,185,654 |
|
54% |
|
Hagen Brett R |
Chief Accounting Officer |
|
2023-07-19 |
4 |
S |
$3.56 |
$1,218 |
D/D |
(342) |
129,170 |
|
54% |
|
288 Records found
|
|
Page 2 of 12 |
|
|